Trials / Completed
CompletedNCT02275117
A Multicenter Assessment of ALD403 in Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 665 (actual)
- Sponsor
- Alder Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALD403 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-03-01
- Completion
- 2016-11-01
- First posted
- 2014-10-27
- Last updated
- 2020-04-08
- Results posted
- 2020-03-30
Locations
92 sites across 4 countries: United States, Australia, Georgia, New Zealand
Source: ClinicalTrials.gov record NCT02275117. Inclusion in this directory is not an endorsement.